| Identification | Back Directory | [Name]
[(2R,3R,4R,5R)-5-[6-(benzylamino)purin-9-yl]-3,4-dihydroxy-oxolan-2-yl ]methoxyphosphonic acid | [CAS]
13484-66-7 | [Synonyms]
IST5-002
Benzyl-amp
Nsc 255523
Benzyl-adenosine monophosphate
N6-Benzyladenosine-5'-phosphate
5'-Adenylic acid,N-(phenylmethyl)-
N(6)-Benzyladenosine-5'-monophosphate
N6-Benzyladenosine 5'-monophosphate sodium salt
N6–BENZYLADENOSINE-5'-MONOPHOSPHATE SODIUM SALT (BAMP)
[(2R,3R,4R,5R)-5-[6-(benzylamino)purin-9-yl]-3,4-dihydroxy-oxolan-2-yl ]methoxyphosphonic acid
((2R,3S,4R,5R)-5-(6-(benzylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate | [Molecular Formula]
C17H20N5O7P | [MDL Number]
MFCD25541633 | [MOL File]
13484-66-7.mol | [Molecular Weight]
437.34 |
| Chemical Properties | Back Directory | [Boiling point ]
798.5±70.0 °C(Predicted) | [density ]
1.81±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
1.86±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
((2R,3S,4R,5R)-5-(6-(Benzylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl Dihydrogen Phosphate can be useful in the study of phytohormone metabolism in human cells. | [in vivo]
RORγt inverse agonist 29 (intraperitoneal injection, 25-100 mg/kg, daily for 10 days) inhibits tumor growth in prostate cancer xenograft model[1].
| Animal Model: | Prostate cancer (CWR22Rv1) xenograft model[1] | | Dosage: | 25, 50, and 100 mg/kg | | Administration: | Intraperitoneal injection, daily for 10 days | | Result: | Induced massive loss of viable tumor cells and dead rounded cells accumulation.
Induced cell death through apoptosis (shown by fragmented DNA in tumor sections).
Decreased nuclear Stat5a/b content by 60%, 78%, and 90% at 25, 50, and 100 mg/kg, respectively.
|
| [IC 50]
STAT5a: 1.5 μM (IC50); STAT5b: 3.5 μM (IC50) |
|
| Company Name: |
NewCan Biotech Limited
|
| Telephone: |
+86-571-86912261 19975279805 |
| Website: |
https://www.newcanbio.com/ |
|